Optimising the Drosophila S2 Expression System for Production of Therapeutic Vaccines

by Charlotte Dyring, PhD
Volume 10, Issue 2 (Winter 2011-2012)

Continuous cell lines of Drosophila have now been in use for more than two decades as hosts for the expression of heterologous gene products. The most popular are the Schneider lines 2 and 3 (S2, S3) and a few derivatives of the Kc line. These have been widely employed for both stable and transient gene expression. The S2, in particular, is an exceptionally versatile system that has proven to be useful for high-level protein production. S2 cells have been used for the expression and analysis of intracellular, secreted, and membrane-associated proteins. This includes cytokines, antibodies, receptors, and viral antigens. These have all been shown to be authentically-processed, biologically active, and produced to high levels. The cell line is ideally suited for the development and industrial-scale manufacturing of a wide range of biopharmaceuticals including vaccines and therapeutic protein products. Compared to conventional technologies, the strengths of the S2 expression technology lie in its quick access to proteins, excellent protein expression capability, scalability, regulatory-friendliness, and applicability to high cell density perfusion cultivation...

Citation:
Dyring C. Optimising the Drosophila S2 Expression System for Production of Therapeutic Vaccines. BioProcess J, 2011; 10(2): 28-35. http://dx.doi.org/10.12665/J102.Dyring.

Posted online December 22, 2011.